Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FMP2.1 + AS01B
- Development stage
- Unknown
- Lead developer
- Walter Reed Army Institute of Research
- Modality
- Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
FMP2.1 + AS01B is a combination malaria vaccine candidate composed of the recombinant protein antigen FMP2.1, which is based on amino acids 83–531 of the apical membrane antigen 1 (AMA-1) from the 3D7 clone of Plasmodium falciparum, and the proprietary adjuvant system AS01B[3][6][1]. The AMA-1 antigen aims to induce an immune response against blood-stage P. falciparum parasites, while the liposome-based adjuvant system AS01B contains two immunostimulants: 3-O-desacyl-4′-monophosphoryl lipid A (MPL), a TLR4 ligand derived from Salmonella minnesota, and QS21, a purified saponin extract from Quillaja saponaria[4][1]. This combination is designed to enhance both humoral and cellular immune responses to improve protection against malaria infection.
- Other names
- Apical Membrane Antigen 1 (AMA-1) vaccine with AS01B adjuvantFMP2.1 malaria vaccine with AS01BFMP-2.1 malaria vaccine with AS01BFMP 2.1 malaria vaccine with AS01B
02
Targets
AMA1 (Apical membrane antigen 1)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on FMP2.1 + AS01B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FMP2.1 + AS01B.